Cargando…

Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis

OBJECTIVE: To determine if a repeat intraarticular (IA) injection of a tin-117m colloid radiosynoviorthesis (RSO) agent can be safely given in the same joint 12 months after an initial injection for treatment of canine elbow osteoarthritis (OA), and to evaluate the pain reduction effect of the repea...

Descripción completa

Detalles Bibliográficos
Autores principales: Donecker, John, Lattimer, Jimmy C, Gaschen, Lorrie, Aulakh, Karanvir Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691448/
https://www.ncbi.nlm.nih.gov/pubmed/34950571
http://dx.doi.org/10.2147/VMRR.S345144
_version_ 1784618786122366976
author Donecker, John
Lattimer, Jimmy C
Gaschen, Lorrie
Aulakh, Karanvir Singh
author_facet Donecker, John
Lattimer, Jimmy C
Gaschen, Lorrie
Aulakh, Karanvir Singh
author_sort Donecker, John
collection PubMed
description OBJECTIVE: To determine if a repeat intraarticular (IA) injection of a tin-117m colloid radiosynoviorthesis (RSO) agent can be safely given in the same joint 12 months after an initial injection for treatment of canine elbow osteoarthritis (OA), and to evaluate the pain reduction effect of the repeat injection. METHODS AND MATERIALS: Nine client owned dogs with grade 1 or 2 elbow OA were given an IA injection of tin-117m colloid in both elbows, one of which had been treated ≤12 months earlier with the same RSO device. Treatment safety was evaluated by joint fluid analysis at baseline (BL) and at 180 days after treatment, and by urinalysis, CBC, and serum chemistry analysis of diagnostic samples obtained at BL and 180 days. Radiographs, computed tomography, and MRI scans were obtained at BL and 180 days to determine if disease progression differed in elbows given one versus two injections. Clinical response to treatment was assessed subjectively by dog owner responses to the Canine Brief Pain Inventory (CBPI) survey at BL, 90 and 180 days, and objectively by investigator-conducted force plate (FP) analysis of dogs at BL, 90, and 180 days. RESULTS: All post-treatment urinalysis, CBC and clinical chemistry results were within normal ranges. Joint fluid analysis showed a significant (P=0.0411) reduction in the percentage of monocytes at 180 days, consistent with the tin-117m colloid mode of action of apoptosis of pro-inflammatory macrophages at the injection site. There was no significant difference in OA progression in elbows given one or two injections. The treatment success rate was 55.5% (5/9) on day 90 as determined either by CBPI responses or FP analysis, and 66.6% (6/9) on day 180 as determined by FP analysis. CONCLUSION: The tin-117m colloid can be safely given as a repeat injection 12 months after an initial injection, and can potentially provide a durable therapeutic response in dogs with elbow OA.
format Online
Article
Text
id pubmed-8691448
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86914482021-12-22 Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis Donecker, John Lattimer, Jimmy C Gaschen, Lorrie Aulakh, Karanvir Singh Vet Med (Auckl) Original Research OBJECTIVE: To determine if a repeat intraarticular (IA) injection of a tin-117m colloid radiosynoviorthesis (RSO) agent can be safely given in the same joint 12 months after an initial injection for treatment of canine elbow osteoarthritis (OA), and to evaluate the pain reduction effect of the repeat injection. METHODS AND MATERIALS: Nine client owned dogs with grade 1 or 2 elbow OA were given an IA injection of tin-117m colloid in both elbows, one of which had been treated ≤12 months earlier with the same RSO device. Treatment safety was evaluated by joint fluid analysis at baseline (BL) and at 180 days after treatment, and by urinalysis, CBC, and serum chemistry analysis of diagnostic samples obtained at BL and 180 days. Radiographs, computed tomography, and MRI scans were obtained at BL and 180 days to determine if disease progression differed in elbows given one versus two injections. Clinical response to treatment was assessed subjectively by dog owner responses to the Canine Brief Pain Inventory (CBPI) survey at BL, 90 and 180 days, and objectively by investigator-conducted force plate (FP) analysis of dogs at BL, 90, and 180 days. RESULTS: All post-treatment urinalysis, CBC and clinical chemistry results were within normal ranges. Joint fluid analysis showed a significant (P=0.0411) reduction in the percentage of monocytes at 180 days, consistent with the tin-117m colloid mode of action of apoptosis of pro-inflammatory macrophages at the injection site. There was no significant difference in OA progression in elbows given one or two injections. The treatment success rate was 55.5% (5/9) on day 90 as determined either by CBPI responses or FP analysis, and 66.6% (6/9) on day 180 as determined by FP analysis. CONCLUSION: The tin-117m colloid can be safely given as a repeat injection 12 months after an initial injection, and can potentially provide a durable therapeutic response in dogs with elbow OA. Dove 2021-12-17 /pmc/articles/PMC8691448/ /pubmed/34950571 http://dx.doi.org/10.2147/VMRR.S345144 Text en © 2021 Donecker et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Donecker, John
Lattimer, Jimmy C
Gaschen, Lorrie
Aulakh, Karanvir Singh
Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis
title Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis
title_full Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis
title_fullStr Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis
title_full_unstemmed Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis
title_short Safety and Clinical Response Following a Repeat Intraarticular Injection of Tin-117m ((117m)Sn) Colloid in Dogs with Elbow Osteoarthritis
title_sort safety and clinical response following a repeat intraarticular injection of tin-117m ((117m)sn) colloid in dogs with elbow osteoarthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691448/
https://www.ncbi.nlm.nih.gov/pubmed/34950571
http://dx.doi.org/10.2147/VMRR.S345144
work_keys_str_mv AT doneckerjohn safetyandclinicalresponsefollowingarepeatintraarticularinjectionoftin117m117msncolloidindogswithelbowosteoarthritis
AT lattimerjimmyc safetyandclinicalresponsefollowingarepeatintraarticularinjectionoftin117m117msncolloidindogswithelbowosteoarthritis
AT gaschenlorrie safetyandclinicalresponsefollowingarepeatintraarticularinjectionoftin117m117msncolloidindogswithelbowosteoarthritis
AT aulakhkaranvirsingh safetyandclinicalresponsefollowingarepeatintraarticularinjectionoftin117m117msncolloidindogswithelbowosteoarthritis